The use of systemic agents is considered standard of care in patients with moderate to severe psoriasis, and these therapeutic agents are marked by a favorable risk-benefit profile, however, are plagued by high attrition. One questionnaire-based survey of 692 patients who had previously taken a biologic agent found that patients discontinued their medications after 11 to 20.5 months. 1 Our study aims to present additional real-world clinical data regarding the reasons behind discontinuation of these novel agents and the drug survival in an academic setting.A study cohort of 127 patients seen in a 5-year time frame at the departments of dermatology and/or rheumatology between June 2012 and April 2017 was identified by the following inclusion criteria: age greater than or equal to 18-years-old, visit diagnoses related to psoriasis and/or active psoriatic arthritis identified by ICD-9 and ICD-10 codes, and use of etanercept, adalimumab, infliximab, secukinumab, ustekinumab, or apremilast. Patients were excluded if Overall 444 (361, 525) Adalimumab 342 (280, 859) Infliximab 420 (223, 725) Etanercept 497 (364, 880) Secukinumab 504 (240, undecided) Ustekinumab 399 (278, 600) Apremilast 380 (274, 510)Note: P = .6893.

No abstract

No abstract